Farallon Capital Amends Protagonist Therapeutics Stake

TL;DR

**Farallon Capital just updated its Protagonist Therapeutics stake, watch for market reaction.**

AI Summary

Farallon Capital Partners, L.P. filed an amended Schedule 13G/A on February 2, 2024, indicating a change in their ownership of Protagonist Therapeutics, Inc. common stock as of December 31, 2023. This filing, Amendment No. 6, shows Farallon Capital Partners, L.P. is a significant institutional investor in Protagonist Therapeutics, Inc. This matters to investors because large institutional holdings can influence stock stability and signal confidence (or lack thereof) in the company's future prospects.

Why It Matters

This filing updates Farallon Capital Partners, L.P.'s ownership in Protagonist Therapeutics, Inc., providing transparency on a major institutional investor's position, which can impact market perception and trading activity.

Risk Assessment

Risk Level: low — This is a routine amendment to an ownership filing, indicating a change in a passive investment, not a major event like an acquisition or bankruptcy.

Analyst Insight

An investor should note that a significant institutional investor like Farallon Capital Partners, L.P. is adjusting its position in Protagonist Therapeutics, Inc. While this specific filing doesn't detail the change in share count or percentage, it signals ongoing portfolio management. Smart investors would look for the specific changes in ownership percentage and share count in the full filing to understand the magnitude of Farallon's updated stake and consider its implications for their own investment thesis.

Key Players & Entities

• Farallon Capital Partners, L.P. (company) — filing an amendment to their ownership stake
• Protagonist Therapeutics, Inc. (company) — the subject company whose stock is being reported
• December 31, 2023 (date) — the date of the event requiring the filing
• February 2, 2024 (date) — the filing date of the SC 13G/A
• Amendment No. 6 (number) — the specific amendment number for this filing

FAQ

Key Financial Figures

• $0.00001 — ame of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securitie

Filing Documents

• ptgx_13ga.htm (SC 13G/A) — 493KB
• 0000908834-24-000035.txt ( ) — 495KB

From the Filing

SC 13G/A 1 ptgx_13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6) * Protagonist Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74366E102 (Cusip Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) S Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). (Continued on following pages) Page 1 of 37 Pages Exhibit Index Found on Page 36 13G CUSIP No. 74366E102 1 NAMES OF REPORTING PERSONS Farallon Capital Partners, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [ X ]** ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares. Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares. Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares. The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page. 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION California NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER -0- 6 SHARED VOTING POWER 386,653 1 7 SOLE DISPOSITIVE POWER -0- 8 SHARED DISPOSITIVE POWER 386,653 1 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 386,653 1 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) [ ] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.7% 1 12 TYPE OF REPORTING PERSON (See Instructions) PN 1 Includes 5,676 Shares for which Warrants are exercisable within the next 60 days. Excludes 271,824 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note). Page 2 of 37 Pages 13G CUSIP No. 74366E102 1 NAMES OF REPORTING PERSONS Farallon Capital Institutional Partners, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [ X ]** ** The reporting persons making this filing hold an aggregate of 5,734,430 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of 1,500,000 Shares. Due to exercise limitations set forth in the Warrants pursuant to the Beneficial Ownership Limitation (as defined in the Preliminary Note), as of the date of this filing the reporting persons have the right to exercise Warrants for up to an aggregate of 30,679 Shares. Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 9.99% of the class of Shares. The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page. 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION California NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER -0- 6 SHARED VOTING POWER 396,682 1 7 SOLE DISPOSITIVE POWER -0- 8 SHARED DISPOSITIVE POWER 396,682 1 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 396,682 1 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) [ ] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.7% 1 12 TYPE OF REPORTING PERSON (See Instructions) PN 1 Includes 5,982 Shares for which Warrants are exercisable within the next 60 days. Excludes 286,518 Shares for which Warrants are not currently exercisable due to the Beneficial Ownership Limitation (as defined in the Preliminary Note). Page 3 of 37 Pages 13G CUSIP No. 74366E102 1 NAMES OF REPORTING PERSONS Farallon Capital Institutional Partners II, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructio

View Full Filing

View this SC 13G/A filing on SEC EDGAR